Clinical Trial Update: Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

View source ↗

Summary

France granted a temporary authorization for use (ATU) of ramucirumab in combination with paclitaxel for gastric or gastroesophageal junction adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Cyramza (ramucirumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Status: APPROVED_FOR_MARKETING